

Global Nanomedicine Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023

<https://marketpublishers.com/r/G0455902066EN.html>

Date: January 2017

Pages: 93

Price: US\$ 2,500.00 (Single User License)

ID: G0455902066EN

Abstracts

Overview: Nanomedicine is an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 1–1,000 nm range, biochips, and polymer therapeutics.

The majority of nanomedicines used now allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and blood–brain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Market Analysis: The “Global Nanomedicine Market” is estimated to witness a CAGR of 17.1% during the forecast period 2017–2023. The nanomedicine market is analyzed based on two segments – therapeutic applications and regions.

Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.

Therapeutic Application Analysis: Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Key Players: Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.

Competitive Analysis: At present, the nanomedicine market is at a nascent stage – but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits: The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report

provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry Overview
- 1.2 Industry Trends
- 1.3 PEST Analysis

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Total Addressable Market (TAM)
- 3.2 Segmented Addressable Market (SAM)
- 3.3 Related Markets
 - 3.3.1 mHealth Market
 - 3.3.2 Healthcare Analytics Market

4 MARKET OUTLOOK

- 4.1 Overview
- 4.2 Regulatory Bodies and Standards
- 4.3 Government Spending and Initiatives
- 4.4 Porter 5 (Five) Forces

5 MARKET CHARACTERISTICS

- 5.1 Evolution
- 5.2 Ecosystem
 - 5.2.1 Regulatory Process
 - 5.2.2 Clinical Trials
 - 5.2.3 Pricing and Reimbursement
- 5.3 Market Segmentation
- 5.4 Market Dynamics

5.4.1 Drivers

5.4.1.1 Emergence of nanorobotics

5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments

5.4.1.3 Reasonable investments in R&D

5.4.1.4 Increased support from governments

5.4.2 Restraints

5.4.2.1 Long approval process and stringent regulations

5.4.2.2 Problems regarding nanoscale manufacturing

5.4.2.3 Risks related to nanomedicines

5.4.2.4 Undefined regulatory standards

5.4.3 Opportunities

5.4.3.1 Aging population with chronic care needs

5.4.3.2 Population and income growth in emerging countries

5.4.4 DRO – Impact Analysis

6 TRENDS, ROADMAP AND PROJECTS

6.1 Market Trends and Impact

6.2 Technology Roadmap

7 TYPES: MARKET SIZE AND ANALYSIS

7.1 Overview

7.2 Global Nanomedicine Market in Oncology Segment

7.3 Global Nanomedicine Market in Cardiovascular Segment

7.4 Global Nanomedicine Market in Neurology Segment

7.5 Global Nanomedicine Market in Anti-inflammatory Segment

7.6 Global Nanomedicine Market in Anti-infective Segment

7.7 Global Nanomedicine Market in Other Therapeutic Areas

8 TRENDING NANOMEDICINES

8.1 Overview

8.2 Abraxane

8.3 Alimta

8.4 Eligard

8.5 Copaxone

8.6 Rapamune

8.7 Neulasta

- 8.8 Cimzia
- 8.9 AmBisome
- 8.10 Mircera
- 8.11 Pegasys
- 8.12 Emend
- 8.13 Renagel
- 8.14 Ritalin

9 REGIONS: MARKET SIZE AND ANALYSIS

- 9.1 Overview
 - 9.1.1 Global Nanomedicine Market by Geographical Segmentation
- 9.2 Key Leading Countries
 - 9.2.1 US
 - 9.2.2 Germany
 - 9.2.3 Japan

10 VENDOR SCENARIO

11 VENDOR PROFILES

- 11.1 Merck & Co. Inc.
 - 11.1.1 Overview
 - 11.1.2 Business Unit
 - 11.1.3 Geographic Revenue
 - 11.1.4 Recent Developments
 - 11.1.5 SWOT Analysis
 - 11.1.6 Business Strategies
- 11.2 Hoffmann-La Roche Ltd.
 - 11.2.1 Overview
 - 11.2.2 Business Unit
 - 11.2.3 Geographic Revenue
 - 11.2.4 Recent Developments
 - 11.2.5 SWOT Analysis
 - 11.2.6 Business Strategies
- 11.3 Gilead Sciences
 - 11.3.1 Overview
 - 11.3.2 Business Unit
 - 11.3.3 Geographic Revenue

- 11.3.4 Recent Developments
- 11.3.5 SWOT Analysis
- 11.3.6 Business strategies
- 11.4 Novartis AG
 - 11.4.1 Overview
 - 11.4.2 Business Unit
 - 11.4.3 Geographic Revenue
 - 11.4.4 Recent Developments
 - 11.4.5 SWOT Analysis
 - 11.4.6 Business Strategies
- 11.5 Amgen Inc.
 - 11.5.1 Overview
 - 11.5.2 Business Unit
 - 11.5.3 Geographic Revenue
 - 11.5.4 Recent Developments
 - 11.5.5 SWOT Analysis
 - 11.5.6 Business Strategies

12 GLOBAL GENERALIST

- 12.1 Pfizer Inc.
 - 12.1.1 Overview
 - 12.1.2 Recent Developments
 - 12.1.3 Pfizer in 2015
- 12.2 Eli Lilly and Company
 - 12.2.1 Overview
 - 12.2.2 Recent Developments
 - 12.2.3 Eli Lilly and Company in 2015
- 12.3 Sanofi
 - 12.3.1 Overview
 - 12.3.2 Recent Developments
 - 12.3.3 Sanofi in 2015

13 COMPANIES TO WATCH FOR

- 13.1 Nanobiotix SA
 - 13.1.1 Overview
 - 13.1.2 Offering
 - 13.1.3 Recent Developments

13.2 UCB SA

13.2.1 Overview

13.2.2 Offering

13.2.3 Recent Developments

14 MARKET LANDSCAPE

14.1 Market Landscape

14.1.1 Mergers & Acquisitions (M&A)

Annexure

? Abbreviations

Table 1 GLOBAL NANOMEDICINE MARKET REVENUE BY APPLICATION TYPE, 2017-2023 (\$BILLION)

Table 2 IOE HEALTHCARE MARKET REVENUE BY TYPE, 2016-2022 (\$BILLION)

Table 3 TECHNOLOGIES MARKET REVENUE BY TYPE, 2016-2022 (\$BILLION)

Table 4 NETWORK TECHNOLOGIES MARKET REVENUE BY RANGE, 2016-2022 (\$BILLION)

Table 5 SHORT RANGE NETWORK TECHNOLOGIES MARKET REVENUE, 2016-2022 (\$BILLION)

Table 6 IOT HEALTHCARE MARKET REVENUE BY SERVICES, 2016-2022 (\$BILLION)

Table 7 TELEMEDICINE MARKET REVENUE BY TYPE, 2016-2022 (\$BILLION)

Table 8 MERCK & CO. INC.: RECENT DEVELOPMENTS

Table 9 HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS

Table 10 GILEAD SCIENCES: KEY MEDICINES/PRODUCTS

Table 11 GILEAD SCIENCES: PIPELINE PRODUCTS

Table 12 GILEAD SCIENCES: RECENT DEVELOPMENTS

Table 13 NOVARTIS AG: RECENT DEVELOPMENTS

Table 14 AMGEN INC.: RECENT DEVELOPMENTS

Table 15 PFIZER INC.: RECENT DEVELOPMENTS

Table 16 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS

Table 17 MERGER & ACQUISITION, 2014–2015

Chart 1 PEST ANALYSIS OF NANOMEDICINE MARKET

Chart 2 RESEARCH METHODOLOGY OF GLOBAL NANOMEDICINE MARKET

Chart 3 GLOBAL NANOMEDICINE MARKET REVENUE, 2016-2023 (\$BILLION)

Chart 4 SHARE OF ENROLLMENT BY VARIOUS INSURANCE PROGRAMS

Chart 5 PORTERS 5 FORCES ON IOT HEALTHCARE MARKET

Chart 6 EVOLUTION OF NANOMEDICINES

Chart 7 ECOSYSTEM OF IOT HEALTHCARE MARKET

Chart 8 IOT HEALTHCARE MARKET SEGMENTATION

Chart 9 MARKET DYNAMICS – DRIVERS, RESTRAINTS & OPPORTUNITIES

Chart 10 DRO - IMPACT ANALYSIS OF IOT HEALTHCARE MARKET

Chart 11 TECHNOLOGY ROADMAP FOR IOT HEALTHCARE MARKET

Chart 12 NANOMEDICINE MARKET BY THERAPEUTIC APPLICATIONS

Chart 13 GLOBAL NANOMEDICINE MARKET SHARE BY THERAPEUTIC APPLICATIONS 2016

Chart 14 GLOBAL NANOMEDICINE MARKET REVENUE IN ONCOLOGY SEGMENT, 2016-2023 (\$BILLION)

Chart 15 GLOBAL NANOMEDICINE MARKET REVENUE IN CARDIOVASCULAR SEGMENT, 2016-2023 (\$BILLION)

Chart 16 GLOBAL NANOMEDICINE MARKET REVENUE IN NEUROLOGY SEGMENT, 2016-2023 (\$BILLION)

Chart 17 GLOBAL NANOMEDICINE MARKET REVENUE IN ANTI-INFLAMMATORY SEGMENT, 2016-2023 (\$BILLION)

Chart 18 GLOBAL NANOMEDICINE MARKET REVENUE IN ANTI-INFECTIVE SEGMENT, 2016-2023 (\$BILLION)

Chart 19 GLOBAL NANOMEDICINE MARKET REVENUE IN OTHER THERAPEUTIC SEGMENTS, 2016-2023 (\$BILLION)

Chart 20 IOT HEALTHCARE MARKET REVENUE BY TECHNOLOGIES, 2016-2022

Chart 21 SHORT RANGE NETWORK MARKET REVENUE, 2015-2022 (\$BILLION)

Chart 22 GEOGRAPHIC REVENUE IN 2016 (%)

Chart 23 MERCK & CO. INC.: OVERVIEW SNAPSHOT

Chart 24 MERCK & CO. INC.: BUSINESS UNITS

Chart 25 GE: GEOGRAPHIC REVENUE

Chart 26 MERCK & CO. INC.: SWOT ANALYSIS

Chart 27 HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT

Chart 28 HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS

Chart 29 HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE

Chart 30 HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS

Chart 31 GILEAD SCIENCES: OVERVIEW SNAPSHOT

Chart 32 GILEAD SCIENCES: BUSINESS UNITS

Chart 33 GILEAD SCIENCES: GEOGRAPHIC REVENUE

Chart 34 GILEAD SCIENCES: SWOT ANALYSIS

Chart 35 NOVARTIS AG: OVERVIEW SNAPSHOT

Chart 36 NOVARTIS AG: BUSINESS UNITS

Chart 37 NOVARTIS AG: GEOGRAPHIC REVENUE

- Chart 38 NOVARTIS AG: SWOT ANALYSIS
- Chart 39 AMGEN INC.: OVERVIEW SNAPSHOT
- Chart 40 AMGEN INC.: BUSINESS UNITS
- Chart 41 AMGEN INC.: GEOGRAPHIC REVENUE
- Chart 42 AMGEN INC.: SWOT ANALYSIS

I would like to order

Product name: Global Nanomedicine Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023

Product link: <https://marketpublishers.com/r/G0455902066EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0455902066EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970